公开(公告)号：US11969444B2

公开(公告)日：2024-04-30

申请号：US17819214

申请日：2022-08-11

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  A01N1/02 ,  A61P35/00 ,  C07K14/725 ,  C07K16/00 ,  C12N5/0783 ,  C12N15/85 ,  G01N33/50

CPC classification number: A61K35/17 ,  A01N1/0284 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/00 ,  C12N5/0636 ,  C12N15/85 ,  G01N33/5005 ,  C07K2317/24 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2501/04 ,  C12N2501/2302 ,  C12N2502/11 ,  C12N2502/1121 ,  C12N2502/99

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US20220133798A1

公开(公告)日：2022-05-05

申请号：US17548504

申请日：2021-12-11

Applicant: Iovance Biotherapeutics Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  A61P35/00 ,  C07K16/00 ,  C12N15/85 ,  C12N5/0783 ,  C07K14/725 ,  G01N33/50 ,  A01N1/02

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US11179419B2

公开(公告)日：2021-11-23

申请号：US17233290

申请日：2021-04-16

Applicant: Iovance Biotherapeutics Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: C12N5/0783 ,  A01N1/02 ,  G01N33/50 ,  C12N15/85 ,  C07K16/00 ,  C07K14/725 ,  A61K35/17 ,  A61P35/00

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US20210252063A1

公开(公告)日：2021-08-19

申请号：US17233299

申请日：2021-04-16

Applicant: Iovance Biotherapeutics Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  C12N5/0783 ,  A01N1/02 ,  C07K14/725 ,  C07K16/00 ,  C12N15/85 ,  G01N33/50 ,  A61P35/00

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US11026974B2

公开(公告)日：2021-06-08

申请号：US15751440

申请日：2017-10-26

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: C12N5/0783 ,  A01N1/02 ,  A61K35/17 ,  C07K14/725 ,  C07K16/00 ,  C12N15/85 ,  G01N33/50 ,  A61P35/00

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US10517894B2

公开(公告)日：2019-12-31

申请号：US15892331

申请日：2018-02-08

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US11857573B2

公开(公告)日：2024-01-02

申请号：US17819209

申请日：2022-08-11

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  A01N1/02 ,  A61P35/00 ,  C07K14/725 ,  C07K16/00 ,  C12N15/85 ,  C12N5/0783 ,  G01N33/50

CPC classification number: A61K35/17 ,  A01N1/0284 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/00 ,  C12N5/0636 ,  C12N15/85 ,  G01N33/5005 ,  C07K2317/24 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2501/04 ,  C12N2501/2302 ,  C12N2502/11 ,  C12N2502/1121 ,  C12N2502/99

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US11369637B2

公开(公告)日：2022-06-28

申请号：US17548504

申请日：2021-12-11

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  A01N1/02 ,  A61P35/00 ,  C07K14/725 ,  C07K16/00 ,  C12N15/85 ,  C12N5/0783 ,  G01N33/50

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US11351199B2

公开(公告)日：2022-06-07

申请号：US17547192

申请日：2021-12-09

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  A01N1/02 ,  A61P35/00 ,  C07K14/725 ,  C07K16/00 ,  C12N15/85 ,  C12N5/0783 ,  G01N33/50

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US11351198B2

公开(公告)日：2022-06-07

申请号：US17480919

申请日：2021-09-21

Applicant: Iovance Biotherapeutics Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  A01N1/02 ,  A61P35/00 ,  C07K14/725 ,  C07K16/00 ,  C12N15/85 ,  C12N5/0783 ,  G01N33/50

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.